Immix Biopharma, Inc. (NasdaqCM: IMMX)
Health Care · Biotechnology · US
$14.47
+5.93% today · +550.5% 1Y
Immix Biopharma, Inc. (NasdaqCM: IMMX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $977.23M and employs 21 people.
Over the last twelve months the share price has gained 550.5%, trading between 1.94 and 13.76.
Tweenvest scores Immix Biopharma, Inc. across four factors: quality 26/100. Its strongest factor is quality.
IMMX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $977.23M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.83
- Dividend yield
- —
- Beta (5Y)
- 0.11
- 52-week high
- $13.76
- 52-week low
- $1.94
- Avg volume (3M)
- —
- Shares outstanding
- 71.54M
- Employees
- 21
- Next earnings
- —
About Immix Biopharma, Inc.
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies. Operating in both the United States and Australia, their primary focus areas are oncology (cancer) and inflammatory diseases. Their product pipeline includes IMX-110, which is currently undergoing Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and various solid tumors. They are also developing IMX-111, a targeted biologic agent for colorectal cancers, and IMX-120, another tissue-specific biologic designed to address ulcerative colitis and severe Crohn's disease. In a strategic move, the company has forged a clinical collaboration and supply agreement with BeiGene Ltd. This partnership aims to conduct a Phase 1b combination clinical trial, evaluating IMX-110 in conjunction with BeiGene's anti-PD-1 drug, Tislelizumab, for solid tumor indications. Founded in 2012, Immix Biopharma maintains its headquarters in Los Angeles, California.
- ISIN
- US45258H1068
- Founded
- 2012
- Listed since
- Dec 16, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €894.20 | +1.71% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.